首页> 外文会议>International Mass Spectrometry Conference >DATA INDEPENDENT ACQUISITION MODES FOR IDENTIFICATION, QUANTIFICATION AND MONITORING OF LOW-ABUNDANCE HOST CELL PROTEINS DURING MONOCLONAL ANTIBODY BIOPROCESSING
【24h】

DATA INDEPENDENT ACQUISITION MODES FOR IDENTIFICATION, QUANTIFICATION AND MONITORING OF LOW-ABUNDANCE HOST CELL PROTEINS DURING MONOCLONAL ANTIBODY BIOPROCESSING

机译:单克隆抗体生物处理期间低丰度宿主细胞蛋白的鉴定,定量和监测数据无关的采集模式

获取原文

摘要

Quantification of large molecular weight biotherapeutics in biological matrices relies mostly on enzymelinked immunosorbent assays (ELISAs) mainly due to several advantages: good sensitivity (1-10 ppm), highthroughput, ease-of-use and low cost per sample. In the case of low-abundance protein impurities (HCPs) present in protein therapeutics (e.g. mAbs), these biological assays typically provide the total HCP concentration (usually expressed in ppm or ng HCP/mg mAb), but ELISAs cannot identify and measure individual HCP contaminants. Several MS-based assays have been recently developed to cover this knowledge gap [1-2]. Here we explored the capabilities of a single dimension chromatographic assay, coupled with mass spectrometry using two different data independent acquisition modes for detection of peptide precursors and their fragments.
机译:生物基质中大分子量生物治疗方法的定量主要依赖于酶免疫吸附试验(ELISAS),主要是由于若干优点:良好的敏感性(1-10ppm),高持续,易用和每种样品的低成本。在蛋白质治疗剂(例如MAb)中存在的低丰度蛋白质杂质(HCP)的情况下,这些生物测定通常提供总HCP浓度(通常以PPM或NG HCP / Mg mab表示),但ELISA不能识别和测量个体HCP污染物。最近已经开发了几种基于MS的测定以涵盖这一知识间隙[1-2]。在这里,我们探讨了单尺寸色谱测定的能力,使用两种不同的数据无关采集模式与质谱相结合,用于检测肽前体及其片段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号